Bucala; Richard J.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Bucala; Richard J..The latest application filed is for "mif modulators".

Company Profile

4.39.33

Bucala; Richard J. - Cos Cob CT
- Cos Cob CT US
Bucala; Richard J. - New York NY
Bucala; Richard J - Cos Cob CT

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Mif Modulators App 20200377457 - Jorgensen; William L. ; et al.	2020-12-03
Mif Modulators App 20190270706 - Jorgensen; William L. ; et al.	2019-09-05
MIF modulators Grant 10,202,343 - Jorgensen , et al. Feb	2019-02-12
Mif Modulators App 20180162813 - Jorgensen; William L. ; et al.	2018-06-14
Methods And Compositions For Using Mhc Class Ii Invariant Chain Polypeptides As A Receptor For Macrophage Migration Inhibitory Factor App 20180105593 - Bucala; Richard J. ; et al.	2018-04-19
MIF modulators Grant 9,643,922 - Jorgensen , et al. May 9, 2	2017-05-09
MIF modulators Grant 9,540,322 - Jorgensen , et al. January 10, 2	2017-01-10
Compositions and Methods for Diagnosing and Treating Diseases and Disorders Associated With D-DT App 20160258966 - Bucala; Richard J. ; et al.	2016-09-08
Macrophage Migration Inhibitory Factor (mif) Promoter Polymorphism In Inflammatory Disease App 20160201130 - Baugh; John A. ; et al.	2016-07-14
Method Of Inhibiting Binding Or Activity Of Mif By Administering A Mif Antagonist App 20160152708 - Bucala; Richard J. ; et al.	2016-06-02
Methods of administering D-dopachrome tautomerase (D-DT) to treat ischemia-reperfusion injury Grant 9,308,255 - Bucala , et al. April 12, 2	2016-04-12
Method of inhibiting binding or activity of MIF by administering a MIF antagonist Grant 9,221,903 - Bucala , et al. December 29, 2	2015-12-29
Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease Grant 9,139,877 - Baugh , et al. September 22, 2	2015-09-22
Methods And Compositions For Using Mhc Class Ii Invariant Chain Polypeptides As A Receptor For Macrophage Migration Inhibitory Factor App 20150010570 - Bucala; Richard J. ; et al.	2015-01-08
MIF antagonists Grant 8,779,099 - Bucala , et al. July 15, 2	2014-07-15
Method Of Inhibiting Binding Or Activity Of Mif By Administering A Mif Antagonist App 20140178403 - Bucala; Richard J. ; et al.	2014-06-26
Compositions and Methods for Diagnosing and Treating Diseases and Disorders Associated With D-DT App 20140030266 - Bucala; Richard J. ; et al.	2014-01-30
Method of inhibiting binding or activity of MIF by administering a MIF antagonist Grant 08617822 -	2013-12-31
Method of inhibiting binding or activity of MIF by administering a MIF antagonist Grant 8,617,822 - Bucala , et al. December 31, 2	2013-12-31
Macrophage Migration Inhibitory Factor (mif) Promoter Polymorphism In Inflammatory Disease App 20130189678 - Baugh; John A. ; et al.	2013-07-25
Inhibition Of Migration Inhibitory Factor In The Treatment Of Diseases Involving Cytokine-mediated Toxicity App 20120149044 - Bucala; Richard J. ; et al.	2012-06-14
Methods And Compositions For Using Mhc Class Ii Invariant Chain Polypeptides As A Receptor For Macrophage Migration Inhibitory Factor App 20120039914 - Bucala; Richard J. ; et al.	2012-02-16
Mif Modulators App 20120040974 - Jorgensen; William L. ; et al.	2012-02-16
Inhibition Of Migration Inhibitory Factor In The Treatment Of Diseases Involving Cytokine-mediated Toxicity App 20120028281 - Bucala; Richard J. ; et al.	2012-02-02
Mif Modulators App 20120004261 - Jorgensen; William L. ; et al.	2012-01-05
Methods And Compositions For Using Mhc Class Ii Invariant Chain Polypeptide As A Receptor For Macrophage Migration Inhibitory Factor App 20110020321 - BUCALA; Richard J. ; et al.	2011-01-27
Mif Modulators App 20100267714 - Jorgensen; William L. ; et al.	2010-10-21
Method for determining MIF content App 20100184091 - Bucala; Richard J. ; et al.	2010-07-22
Method for screening for compounds using MHC class II invariant chain polypeptide and macrophage migration inhibitory factor Grant 7,741,057 - Bucala , et al. June 22, 2	2010-06-22
Methods and Compositions for Using MHC Class II Invariant Chain Polypeptide as a Receptor for Macrophage Migration Inhibitory Factor App 20090263404 - Bucala; Richard J. ; et al.	2009-10-22
Therapeutic uses of factors which inhibit or neutralize MIF activity App 20080317759 - Bucala; Richard J. ; et al.	2008-12-25
Methods and Compositions for Using MHC Class II Invariant Chain Polypeptide as a Receptor for Macrophage Migration Inhibitory Factor App 20080146507 - Bucala; Richard J ; et al.	2008-06-19
Method for determining MIF content App 20060062788 - Bucala; Richard J. ; et al.	2006-03-23
Method for determining MIF content Grant 6,998,238 - Bucala , et al. February 14, 2	2006-02-14
Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor App 20060024754 - Bucala; Richard J. ; et al.	2006-02-02
Therapeutic uses of factors which inhibit or neutralize MIF activity App 20040156848 - Bucala, Richard J. ; et al.	2004-08-12
Therapeutic uses of factors which inhibit or neutralize MIF activity Grant 6,774,227 - Bucala , et al. August 10, 2	2004-08-10
Fibrocyte-base vaccine formulations Grant 6,759,036 - Rice , et al. July 6, 2	2004-07-06
Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity App 20040053843 - Bucala, Richard J. ; et al.	2004-03-18
Fibrocyte-based vaccine formulations App 20040022774 - Rice, Glenn C. ; et al.	2004-02-05
Inducible phosphofructokinase and the warburg effect App 20030228568 - Bucala, Richard J. ; et al.	2003-12-11
Composition containing anti-MIF antibody Grant 6,645,493 - Bucala , et al. November 11, 2	2003-11-11
Compounds having MIF antagonist activity Grant 6,599,938 - Al-Abed , et al. July 29, 2	2003-07-29
Inducible phosphofructokinase and the Warburg effect Grant 6,596,851 - Bucala , et al. July 22, 2	2003-07-22
Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity App 20030099653 - Bucala, Richard J. ; et al.	2003-05-29
Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor App 20030013122 - Bucala, Richard J. ; et al.	2003-01-16
Compounds and compositions for treating tissue ischemia App 20020193412 - Tracey, Kevin J. ; et al.	2002-12-19
Inducible phosphofructokinase and the Warburg effect Grant 6,413,939 - Bucala , et al. July 2, 2	2002-07-02
Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis Grant 6,410,598 - Vitek , et al. June 25, 2	2002-06-25
Immunological advanced glycation endproduct crosslink Grant 6,380,165 - Al-Abed , et al. April 30, 2	2002-04-30
Immunological Advanced Glycation Endproduct Crosslink App 20020022234 - AL-ABED, YOUSEF ; et al.	2002-02-21
Blood-borne mesenchymal cells Grant 6,174,526 - Cerami , et al. January 16, 2	2001-01-16
Diagnostic assays for MIF Grant 6,080,407 - Bucala , et al. June 27, 2	2000-06-27
Modulation of immune responses in blood-borne mesenchymal cells Grant 6,054,121 - Cerami , et al. April 25, 2	2000-04-25
Combination method for treating diseases caused by cytokine-mediated toxicity Grant 6,030,615 - Bucala , et al. February 29, 2	2000-02-29
Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts Grant 5,935,927 - Vitek , et al. August 10, 1	1999-08-10
Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom Grant 5,869,534 - Bucala , et al. February 9, 1	1999-02-09
Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts Grant 5,850,840 - Cerami , et al. December 22, 1	1998-12-22
Vaccine adjuvant Grant 5,849,307 - Metz , et al. December 15, 1	1998-12-15
Blood-borne mesenchymal cells Grant 5,846,796 - Cerami , et al. December 8, 1	1998-12-08
Glycosylation of lipids and lipid-containing particles and diagnostic and therapeutic methods and materials derived therefrom Grant 5,780,615 - Bucala , et al. July 14, 1	1998-07-14
Methods and materials for the diagnosis and treatment of conditions such as stroke Grant 5,733,933 - Bucala , et al. March 31, 1	1998-03-31
Methods and materials for the diagnosis and treatment of conditions such as stroke Grant 5,733,524 - Bucala , et al. March 31, 1	1998-03-31
Immunochemical detection of in vivo advanced glycosylation endproducts Grant 5,712,101 - Bucala January 27, 1	1998-01-27
Methods and materials for the diagnosis and treatment of conditions such as stroke Grant 5,700,447 - Bucala , et al. December 23, 1	1997-12-23
Blood-borne mesenchymal cells Grant 5,654,186 - Cerami , et al. August 5, 1	1997-08-05
Method for detecting hemoglobin advanced glycosylation endproducts Grant 5,610,076 - Founds , et al. March 11, 1	1997-03-11

Company Registrations

NCAGE Code	4BKE9	BUCALA RICHARD J
CAGE Code	4BKE9	BUCALA, RICHARD J

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.